Leading Paragon Biosciences since 2010, Jeff Aronin has helped further establish a new paradigm in biotech, which has led to a focused, patient-centric drug development strategy. The strategy helps to more efficiently bring forward important science for patients with unmet needs (Linkedin).
Paragon and its portfolio companies are focused on understanding the underlying cause of diseases, especially those affecting people who have few or no treatment options. Jeff and the team then seeks breakthrough science, partnering with innovative researchers around the world to identify novel ways to address serious illness. Once that is accomplished, Paragon sets out to finance and incubate promising biotech companies that are focused on bringing medicines to market.
Two of Paragon’s lead companies are Castle Creek Pharmaceuticals and Harmony Biosciences. Castle Creek is focused on rare genetic dermatology disorders and Harmony is focused on central nervous system disorders. Whether it is addressing the underlying causes of epidermolysis bullosa simplex (in the case of Castle Creek) or narcolepsy and cataplexy (in the case of Harmony), Paragon’s companies are doing important work to bring additional options for patents in need.
Beyond Paragon, Jeff Aronin has nearly two decades of experience in the biotech industry spent discovering and developing medicines that have helped tens of thousands of patients live better. At Paragon, the leadership team has secured 13 new drug approvals, a rate on par with or better than most large biotech and pharma companies.